Following a decision by Bayer’s supervisory board, the contract of CEO Bill Anderson has been extended until March 31, 2029. This extension, adding three years to his previous contract set to expire in March 2026, reflects the company’s confidence in his leadership and strategic vision.
Anderson, who was appointed CEO in 2023, has implemented structural reforms and new strategies that have significantly contributed to Bayer’s financial turnaround. These efforts have driven approximately a 6% increase in Bayer’s stock price over the past year.
The extension also signals Bayer’s commitment to continuity in leadership as the company navigates ongoing challenges in the pharmaceutical and agricultural sectors, aiming for sustained growth and innovation under Anderson’s guidance.
